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Abstract: 
Marfan syndrome is a spectrum of disorder caused by a heritable genetic defect of connective tissue that has an 
autosomal dominant mode of transmission. The defect itself has been isolated to FBN1 gene on chromosome 15, 
which codes for connective tissue protein FIBRIN. A mutation result in an increase in protein called transforming 
growth factor ß. Abnormalities in this protein cause a myriad of distinct clinical problems, of which the 
musculoskeletal, cardiac and ocular system problems predominate. A case report on Marfan syndrome with 
mediastinal widening and sinus tachycardia was reported. This report underscores the significance of thorough 
family history and physical examination in the diagnosis of Marfan syndrome. Additionally, the effectiveness of 
therapy can be improved by having a proper insight about the pathology and clinical presentation of Marfan 
syndrome. Regular ECG, blood pressure monitoring and early initiation of beta blockers therapy as well as elective 
prophylactic surgical repair contribute to increasing the survival rate of Marfan patients. 
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INTRODUCTION:  
Marfan syndrome is an inherited disorder that affects 
connective tissue — the fibers that support and 
anchor your organs and other structures in your body. 
Marfan syndrome frequently affects the heart, eyes, 
blood vessels and skeleton. About 1 in 5000 people 
have marfan syndrome, including men and women of 
all race and ethnic groups. Some people can have 
marfan syndrome due to spontaneous mutation, and 
will be first to have this disease in their family[1]. 
There is a 50% chance of passing this mutation to 
progeny. People are born with marfan syndrome, but 
they may not notice any features until later in life. Its 
features include musculoskeletal:-long arms, legs and 
fingers, tall and thin body, curved spine, flat feet, 
chest sinks in or sticks out and crowded teeth. 
Cardiac: aortic root dilation, dissection. Eyes:- 
myopia, lens dislocation[2,3]. 
Diagnosis is based on examining both physical 
features and genetic/family history. The signs and 
symptoms are compared against ghent criteria. This 
diagnostic tool consists of major and minor criterias. 
Major criteria include enlarged aorta, dislocation of 
lens, family history, and musculoskeletal problems 
such as scoliosis (or flat feet). Minor criteria include 
myopia, long and thin face, loose joints, a high 
arched plate and unexplained stretch marks. Other 
diagnostic tool include echocardiogram and chest x-
ray[4,5]. Standard medical therapy for marfan 
syndrome consist of ß –blockers which lowers heart 
rate, blood pressure and reducing wall of aorta. New 
treatment as a second option include ARB blocker-
losartan which is an important alternative therapy to 
patient intolerant to ß –blocker. Aortic root surgery is 
also prefered. 
 
CASE REPORT: 
A 21yr old young man was admitted in PMC hospital 
with complaints of tenderness in epigastric region, 
abdominal pain, vomiting and difficulty in 
swallowing. On preliminary examination itself the 
patient was found to have marfaroid features, long 
arms, legs and crowded teeth[6].  
On investigating family history, the patient was 
found to be the tallest one of all the family members. 
No family history for marfan syndrome was found.  
On general examination his B.P chart revealed 
increased systolic BP and Chest x-ray showed 
mediastinal widening and ECG shows sinus 
tachycardia. On final diagnosis patient was found to 
have acid peptic disease (upper GI endoscopy –
ulceration) and marfan syndrome. He was treated 
with Syp.Sucralfate 10 ml, Inj.Pantoprazole 40 mg, 
T.Vitamin B 12 and T. Atenolol 25 mg. 
He was discharged after 6 days of hospital admission. 
After 3 weeks the patient consulted in the 
ophthalmology department of same hospital as he 
experienced some visual problems. On investigation 
he was found to have myopia or nearsightedness and 
dislocated lens (supra temporal).  
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LAB PARAMETERS 
 
PARAMETER PATIENT VALUE 
HAEMATOLOGY 
 
Hb 14.4 
RBC 5.25 X 106 
Plt 216 X 10³ 
MCV 80.2 
MCH 27.2 
MCHC 34 
BIOCHEMISTRY 
 
B.Urea 29 
S.Creatinine 0.8 
DIFFERENTIAL COUNT: 
 
%L 22.0% 
%M 6.5%  
%G 71.5% 
ESR 30 
URINE ANALYSIS: 
 
Sugar Nil 
Pus cells 2-4 
Epithelial cells 1-2 
LIVER FUNCTION TEST 
 
S.T Protein 7.6 
S.T Albumin 4.8 
S.T Globulin 2.8 
S.T Bilirubin 0.7 
SGPT 21 
SGOT 17 
S. Alkaline phosphatase 97 
 
CHEST X-RAY                                                                                    ECG 
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DISCUSSION: 
Marfan syndrome is an autosomal inherited 
connective tissue disorder with diverse clinical 
manifestations. Although various studies have been 
conducted which aimed at improving the medical 
aspect of management, those trials produced 
conflicting results and generally involved relatively 
few patients.  
In this report the patient received symptomatic 
treatment; Tablet Atenolol was given for treating 
mediastinal widening and increased systolic BP. For 
acid peptic disease he was managed with syrup 
Sucralfate and Injection pantoprazole. Laboratory 
investigation revealed elevated monocytes and ESR 
count but no treatment was provided. He presented 
with complaints of vomiting on admission but no 
anti-emetics were given. On discharge he was 
prescribed with Tablet Atenolol 25mg BD, Syrup 
sucralfate 10ml TID and tablet Pantoprazole 40mg 
OD and review after 1 week. 
Three weeks later he experienced visual problems 
and consulted ophthalmology department of same 
hospital for further evaluation where he was found to 
have myopia and dislocated lens. Opthalmologist 
advised for eye glasses and periodic monitoring. 
Myopia and dislocated lens are the symptoms of 
disease progression of marfan syndrome. 
 
CONCLUSION: 
 
This report underscores the significance of thorough 
family history and physical examination in the 
diagnosis of Marfan syndrome. Additionally, the 
effectiveness of therapy can be improved by having a 
proper insight about the pathology and clinical 
presentation of Marfan syndrome. Regular ECG, 
blood pressure monitoring and early initiation of beta 
blockers therapy as well as elective prophylactic 
surgical repair contribute to increasing the survival 
rate of Marfan patients. Opthalmologic examination 
periodically to assess the disease progression is also 
necessary. New studies points out the treatment with 
second option includes ARB blocker-losartan as an 
important alternative therapy to patient intolerant to ß 
–blocker. Aortic root surgery is also preferred 
treatment for this. 
 
ACKNOWLEDGEMENT 
We take this opputunity to express our sincere 
gratitude to all the faculty members who gave us 
support and assistance to publish this case report. 
 
CONFLICT OF INTERESTS 
The author declares no conflict of interest   
 
REFERENCES: 
 
1.Collod-Béroud G, Boileau C. Marfan syndrome in 
the third Millennium. Eur J Hum Genet. 2002 
November; 10(11):673–681.  
2.“MedlinePlus Encyclopedia: Marfan Syndrome,” 
http://www.nlm.nih.gov/. 
3.Lacro RV, Dietz HC, Wruck LM, Bradley TJ, et al. 
Rationale and Design of a Randomized Clinical Trial 
of Beta Blocker Therapy (Atenolol) vs. Angiotensin 
II Receptor Blocker Therapy (Losartan) in 
Individuals with Marfan Syndrome. Am Heart J. 
2007 October; 154(4):624–631.  
4.Gould RA, Sinha R, Aziz H, Rouf R, Dietz HC 3rd, 
Judge DP, et al. Multi-scale biomechanical 
remodeling in aging and genetic mutant murine 
mitral valve leaflets: insights into marfan 
syndrome. PLoS One. 2012. 7(9):e44639.  Murdoch 
JL, Walker BA, Halpern BL, Kuzma JW, McKusick 
VA. Life expectancy and causes of death in the 
Marfan syndrome. N Engl J Med. 1972 Apr 13. 
286(15):804-8. 
5.Judge DP, Dietz HC. Therapy of Marfan 
syndrome. Annu Rev Med. 2008 Feb 18. 59:43-59.  
6.McKusick VA. The cardiovascular aspects of 
Marfan's syndrome: a heritable disorder of 
connective tissue. Circulation. 1955 Mar. 11(3):321-
42.  
 
